Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.54 |
| ▸ | BRD2 | P25440 | 2/20 | 0.54 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619143 | 1.00 | BRD4 (0.54) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619060 | 1.00 | BRD4 (0.54) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL13733901 | 0.87 | BRD4 (0.56) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619818 | 0.86 | BRD4 (0.51) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16618942 | 0.86 | BRD4 (0.51) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16618943 | 0.86 | BRD4 (0.51) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16774314 | 0.80 | BRD4 (0.58) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619461 | 0.80 | BRD4 (0.64) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967453 | 0.79 | BRD4 (0.50) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL17967397 | 0.79 | BRD4 (0.50) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015049629-A1 | IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS | Piramal Enterprises Limited (IN) | 2015-04-09 | — | — | WO | disclosed |